The Mechanism of Anti-Epileptogenesis by Levetiracetam Treatment is Similar to the Spontaneous Recovery of Idiopathic Generalized Epilepsy during Adolescence

키워드

참고문헌 (37)

1. Loscher W, "Current status and future directions in the pharmacotherapy of epilepsy", Trends Pharmacol Sci, 23, pp.113~118 (2002)
2. Sasa M, "A new frontier in epilepsy : novel antiepileptogenic drugs", J Pharmacol Sci, 100, pp.487~494 (2006)
3. Armijo JA, "Ion channels and epilepsy", Curr Pharm Des, 11, pp.1975~2003 (2005)
4. Weaver DF, "Epileptogenesis, ictogenesis and the design of future antiepileptic drugs", Can J Neurol Sci, 30, pp.4~7 (2003)
5. Koyama R, "Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus", J Neurosci, 24, pp.7215~7224 (2004)
6. Scharfman H, "Ectopic granule cells of the rat dentate gyrus", Dev Neurosci, 29, pp.14~27 (2007)
7. Wang FJ, "Selective Upregulation of Brain-derived Neurotrophic Factor(BDNF)Transcripts and BDNF Direct Induction of Activity Independent N-Methyl-D-aspartate Currents in Temporal Lobe Epilepsy Patients with Hippocampal Sclerosis", J Int Med Res, 39, pp.1358~1368 (2011)
8. Engel T, "Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis?", Int J Physiol Pathophysiol Pharmacol, 1, pp.97~115 (2009)
9. John GR, "IL-1-regulated responses in astrocytes : relevance to injury and recovery", Glia, 49, pp.161~176 (2005)
10. Kono H, "How dying cells alert the immune system to danger", Nat Rev Immunol, 8, pp.279~289 (2008)
11. Schroder K, "The inflammasomes", Cell, 140, pp.821~832 (2010)
12. Eisenstein M, "Genetics: finding risk factors", Nature, 475, pp.S20~S22 (2011)
13. Rock KL, "The sterile inflammatory response", Annu Rev Immunol, 28, pp.321~342 (2010)
14. Vezzani A, "ICE", caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy, 2010, pp.11, 43~50
15. Ryoo HD, "Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways", Dev Cell, 7, pp.491~501 (2004)
16. Meidenbauer JJ, "The EL mouse : a natural model of autism and epilepsy", Epilepsia, 52, pp.347~357 (2011)
17. Murashima YL, "Developmental program of epileptogenesis in the brain of EL mice", Epilepsia, 46(Suppl 5), pp.10~16 (2005)
18. Murashima YL, "Role of cytokines during epileptogenesis and in the transition from the interictal to the ictal state in the epileptic mutant EL mouse", Gene Regul Syst Bio, 2, pp.267~274 (2008)
19. Murashima YL, "Cell cycle reentry and cell proliferation as candidates for the seizure predispositions in the hippocampus of EL mouse brain", Epilepsia, 48(Suppl 5), pp.119~125 (2007)
20. Bozzi Y, "Cell signaling underlying epileptic behavior", Front Behav Neurosci, 5, pp.45~ (2011)
21. Muller FJ, "Regulatory networks define phenotypic classes of human stem cell lines", Nature, 455, pp.401~405 (2008)
22. Kaminski RM, "Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam", Epilepsia, 50, pp.1729~1740 (2009)
23. van Vliet EA, "Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy", Epilepsia, 50, pp.422~433 (2009)
24. de Groot M, "Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex", Neuro Oncol, 12, pp.265~273 (2010)
25. Schulze-Bonhage A, "Brivaracetam for the treatment of epilepsy", Expert Opin Pharmacother, 12, pp.1959~1966 (2011)
26. Noyer M, "The novel antiepileptic drug levetiracetam(ucb L059)appears to act via a specific binding site in CNS membranes", Eur J Pharmacol, 286, pp.137~146 (1995)
27. Lynch BA, "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam", Proc Natl Acad Sci U S A, 101, pp.9861~9866 (2004)
28. Ji-qun C, "Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs", Epilepsia, 46, pp.1362~1370 (2005)
29. Yan HD, "Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat(SER)", Epilepsia, 46, pp.1170~1177 (2005)
30. Husum H, "Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1-and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling : implications for antiepileptogenic and mood-stabilizing properties", Epilepsy Behav, 5, pp.204~215 (2004)
31. Noda A, "NER rat strain : a new type of genetic model in epilepsy research", Epilepsia, 39, pp.99~107 (1998)
32. Okumura H, "Expression analysis of SV2A and SNARE-related proteins in Noda epileptic rat (NER), a rat model of generalized tonic-clonic seizure", Joint congress of the 21st congress of Japanese society of clinical neuropsychopharmacology and the 41st annual meeting of Japanese society of neuropsychopharmacology, pp.178~ (2011)
33. Crino PB, "Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia", Neurology, 56, pp.906~913 (2001)
34. Law AJ, "Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation", Eur J Neurosci, 18, pp.1197~1205 (2003)
35. Jope RS, "Glycogen synthase kinase-3(GSK3)in psychiatric diseases and therapeutic interventions", Curr Drug Targets, 7, pp.1421~1434 (2006)
36. Noh JS, "Neurotoxic and neuroprotective actions of catecholamines in cortical neurons", Exp Neurol, 159, pp.217~224 (1999)
37. Qing H, "The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis", Eur J Neurosci, 17, pp.1563~1570 (2003)

관련 논문AI추천